CoChat

Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study

Open access
Del Prato, S., Camisasca, R., Wilson, C., Fleck, P. · 2014 · Diabetes, Obesity and Metabolism
Cited by 87

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Aims: To evaluate the long‐term durability of the efficacy of alogliptin compared with glipizide in combination with metformin in people with type 2 diabetes inadequately controlled on stable‐dose metformin. Methods: This multicentre, double‐blind, active‐controlled study randomized 2639 patients aged 18–80 years to 104 weeks of treatment with metformin in addition to alogliptin 12.5 mg once daily (n = 880), alogliptin 25 mg once daily (n = 885) or glipizide 5 mg once daily, titrated to a maximum of 20 mg (n = 874). The primary endpoint was least square mean change from baseline in HbA1c level at 104 weeks. Results: The mean patient age was 55.4 years, the mean diabetes duration was 5.5 years and the mean baseline HbA1c was 7.6%. HbA1c reductions at week 104 were −0.68%, −0.72% and −0.59% for alogliptin 12.5 and 25 mg and glipizide, respectively [both doses met the criteria for non‐inferiority to glipizide (p<0.001); alogliptin 25 mg met superiority criteria (p=0.010)]. Fasting plasma glucose concentration decreased by 0.05 and 0.18 mmol/l for alogliptin 12.5 and 25 mg, respectively, and increased by 0.30 mmol/l for glipizide (p < 0.001 for both comparisons with glipizide). Mean weight changes were −0.68, −0.89 and 0.95 kg for alogliptin 12.5 and 25 mg and glipizide, respectively (p < 0.001 for both comparisons with glipizide). Hypoglycaemia occurred in 23.2% of patients in the glipizide group vs. 2.5 and 1.4% of patients in the alogliptin 12.5 and 25 mg groups, respectively. Pancreatitis occurred in one patient in the alogliptin 25 mg group and three in the glipizide group. Conclusions: Alogliptin efficacy was sustained over 2 years in patients with inadequate glycaemic control on metformin alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12377

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 12

  1. 10.2337/dc12-0413 · DOI · Paper page
  2. 10.2337/dc08-1035 · DOI · Paper page
  3. 10.1111/j.1742-1241.2008.01933.x · DOI · Paper page
  4. 10.1111/j.1463-1326.2011.01463.x · DOI
  5. 10.1111/j.1532-5415.2009.02484.x · DOI · Paper page
  6. 10.1111/j.1463-1326.2009.01124.x · DOI · Paper page
  7. Takeda Pharmaceuticals America, Inc., 2013, Nesina (alogliptin) Tablets. Package Insert
  8. 10.1111/ijcp.12119 · DOI
  9. Food and Drug Administration, 2008, Guidance For Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
  10. 10.1111/dom.12093 · DOI · Paper page
  11. 10.1007/s00125-011-2447-3 · DOI
  12. 10.1185/030079905X49662 · DOI

Cited by

See all 87

Metadata

Authors
Del Prato, S., Camisasca, R., Wilson, C., & Fleck, P.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2014-09-25
Volume
16
Issue
12
Pages
1239-1246
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1981478931
Cited by
87
References
5
FWCI
9.34
Type
journal article
Language
en
Open access
hybrid
Funders
Takeda Development Center Americas, Inc (N/A)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. https://app.cochat.ai/papers/10.1111/dom.12377
The paper
Del Prato, S., Camisasca, R., Wilson, C., & Fleck, P. (2014). Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12377

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.